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Introduction. Several studies showed that aberrant miRNA expression is associated with 
development and progression of  hepatocellular carcinoma (HCC). 
Aim. To examine whether some commonly deregulated miRNAs (miR-122, miR-21, miR-
221 and miR-16) in HBV-related HCC may serve as diagnostic markers. 
Materials and Methods. Serum expression of miR-122, miR-21, miR-221 and miR-16 was 
evaluated by real-time quantitative RT-PCR in 33 patients with HBV-related HCC (61±10 
years; F/M=4/29), 30 patients with HBV-related cirrhosis (53±11 years; F/M=11/19) and 27 
blood donors as healthy controls (54±8 years; F/M=9/18). 
Results. Median levels of miR-16, miR-122 and miR-221 were significantly different in 
patients with HCC or cirrhosis compared to healthy controls (p<0.001) whereas, only miR-
122 levels differed in patients with HCC from cirrhotic patients (p=0.024). miR-122 levels 
were significantly higher in patients with multifocal HCC than in patients with a single 
lesion  (p=0.024). Expression levels of mir-21 were similar in the 3 groups. Area under the 
curve (AUC) analysis showed that serum levels of miR-122, miR-122+miR-221, miR-
122+miR-16 and miR-122+miR-221+miR-16, are able to differentiate patients with HCC 
from patients with cirrhosis (AUC=0.675; AUC=0.704; AUC=0.681; AUC=0.703, 
respectively). Moreover, miR-16, miR-122 and miR-221, alone or in combination, were able 
to discriminate patients with HCC or cirrhosis from healthy controls (AUC>0.9). In addition, 
a correlation between miR-122 levels and HCC nodules number (R=0.390; p=0.036), and 
between miR-16 and miR-122 levels, and ALT values (R= -0.464, p=0.034; R=0.449, 
p=0.536, respectively) was found. 
Conclusions. Among the four microRNAs analyzed, only miR-122 significantly 
discriminates patients with HCC from cirrhotic patients and patients with HCC or cirrhosis 
from controls. miR-122 appears to reflect liver necro-inflammation, since we observed a 
positive correlation with ALT levels. Moreover, the correlation between miR-122 expression 
levels and HCC with multi-nodules, suggests the possible use of this miRNA for tumor 
stadiation. Nevertheless, miR-122 AUC values were not sufficiently high for HCC screening 
purposes. 
 
